明德生物拟通过增资并收购取得湖南蓝怡51%股权

Core Viewpoint - Mingde Biological plans to acquire a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for a total transaction price of 35.701 million yuan, making it a subsidiary and included in the consolidated financial statements [1] Group 1: Acquisition Details - The acquisition will be executed through capital increase and equity purchase, with the possibility of acquiring the remaining shares between 2026 and 2028 if certain conditions are met [1] - Hunan Lanyi, established in September 2020, focuses on the research, production, and service of IVD instruments and reagents, and has been recognized as a national high-tech enterprise [1] Group 2: Business Outlook - Hunan Lanyi is currently operating at a loss due to significant R&D investments and strategic market expenditures during its market expansion phase [2] - The inclusion of glycated hemoglobin testing in free health check-ups for individuals aged 65 and above is expected to boost demand from grassroots medical institutions, which, along with growing overseas business, positions the glycated hemoglobin segment as a core growth driver for the company [2]